<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245840</url>
  </required_header>
  <id_info>
    <org_study_id>SHP621-303</org_study_id>
    <nct_id>NCT03245840</nct_id>
  </id_info>
  <brief_title>Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents
      with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302
      extension study. The purpose of this study is to see if BOS is safe and well tolerated over
      the long-term in adolescents and adults with EoE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration to 3 days after last study drug administration (up to Month 48)</time_frame>
    <description>Treatment-emergent adverse event is defined as an adverse event (AE) that starts or deteriorates on or after the date of the first dose of BOS and no later than 3 days following the last dose of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Relevant Changes in Physical Examinations, Vital Signs and Clinical Laboratory Assessments</measure>
    <time_frame>From start of study drug administration to 3 days after last study drug administration (up to Month 48)</time_frame>
    <description>A change in the value of a clinical laboratory or vital sign assessment can represent an AE if the change is clinically relevant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 2 (Month 12)</measure>
    <time_frame>Baseline and Visit 2 (Month 12)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 4 (Month 24)</measure>
    <time_frame>Baseline and Visit 4 (Month 24)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 6 (Month 36)</measure>
    <time_frame>Baseline and Visit 6 (Month 36)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 8 (Month 48)</measure>
    <time_frame>Baseline and Visit 8 (up to Month 48)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 2 (Month 12)</measure>
    <time_frame>Baseline and Visit 2 (Month 12)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram [mcg]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 4 (Month 24)</measure>
    <time_frame>Baseline and Visit 4 (Month 24)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 mcg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 6 (Month 36)</measure>
    <time_frame>Baseline and Visit 6 (Month 36)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 mcg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 8 (Month 48)</measure>
    <time_frame>Baseline and Visit 8 (up to Month 48)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 mcg).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Eosinophilic Esophagitis (EoE)</condition>
  <arm_group>
    <arm_group_label>Budesonide Oral Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be initiated on 10 milliliter (mL) of Budesonide oral suspension (0.2 milligram/mL) twice daily up to 48 months (Visit 8) or early termination (ET).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide oral suspension</intervention_name>
    <description>Budesonide oral suspension (BOS) 10 mL twice daily</description>
    <arm_group_label>Budesonide Oral Suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject completed the SHP621-302 (NCT02736409) extension study and is considered by
             the investigator to potentially benefit from continued BOS investigational treatment.

          -  Subject is able to provide written informed consent (subject, parent or legal guardian
             and, as appropriate, subject assent) to participate in the study before completing any
             study-related procedures.

          -  Females of childbearing potential must agree to continue acceptable birth control
             measures (example (eg): abstinence, surgically sterile male partner, stable oral
             contraceptives, or double-barrier methods) throughout study participation.

          -  Subject is willing and has an understanding and ability to fully comply with study
             procedures and restrictions as defined in protocol.

        Exclusion Criteria:

          -  Subject has changes in medications or diet during the SHP621-302 (NCT02736409) study
             that could affect participation in this continuation study.

          -  Subject anticipates using swallowed topical corticosteroid for EoE or systemic
             corticosteroid for any condition during the treatment period; any temporary use (less
             than or equal to [â‰¤] 7 days) or initiation of new steroid treatment during the study
             should be documented and discussed with the medical monitor prospectively but should
             be avoided within 4 weeks of the scheduled esophagogastroduodenoscopy (EGDs).

          -  Subject anticipates use of Cytochrome P450 3A4 inhibitors (eg, ketoconazole,
             grapefruit juice) during the continuation study.

          -  Subject has an appearance at the EGD at the final treatment evaluation visit of
             SHP621-302 (NCT02736409) (Visit 8) of an esophageal stricture (high grade), as defined
             by the presence of a lesion that does not allow passage of a diagnostic adult upper
             endoscope (eg, with an insertion tube diameter of greater than (&gt;) 9 millimeter [mm]).

          -  Subject has presence of esophageal varices at the EGD at the final treatment
             evaluation visit (Visit 8) of the SHP621-302 (NCT02736409) study.

          -  Subject has any current disease of the gastrointestinal tract, aside from EoE,
             including eosinophilic gastritis, enteritis, colitis, or proctitis, inflammatory bowel
             disease, or celiac disease.

          -  Subject has other diseases causing or associated with esophageal eosinophilia,
             including hypereosinophilic syndrome, collagen vascular disease, vasculitis,
             achalasia, or parasitic infection.

          -  Subject has oropharyngeal or esophageal candidiasis that failed to respond to previous
             treatment. Diagnosis with oropharyngeal or esophageal candidiasis at or since the
             final treatment evaluation visit (Visit 8) of the SHP621-302 (NCT02736409) study is
             not an exclusion as long as the subject is expected to respond to treatment.

          -  Subject has a potentially serious acute or chronic infection or immunodeficiency
             condition, including tuberculosis, fungal, bacterial, viral/parasite infection, ocular
             herpes simplex, or chicken pox/measles.

          -  Subject has upper gastrointestinal bleeding identified at the EGD at the final
             treatment evaluation visit (Visit 8) of the SHP621-302 (NCT02736409) study.

          -  Subject has evidence of active infection with Helicobacter pylori.

          -  Subject has evidence of unstable asthma.

          -  Subject is female and pregnant or nursing.

          -  Subject has a history of intolerance, hypersensitivity, or idiosyncratic reaction to
             budesonide (or any other corticosteroids), or to any other ingredients of the study
             medication.

          -  Subject has a history or high risk of noncompliance with treatment or regular clinic
             visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>1 866-842-5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Del Sol Research Management</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvia Parra</last_name>
      <phone>520-257-3881</phone>
      <email>Eparra@delsolresearch.com</email>
    </contact>
    <investigator>
      <last_name>Gary Gottlieb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Gastroenterology</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Murphy</last_name>
      <email>murphy@arkgi.net</email>
    </contact>
    <investigator>
      <last_name>Robert Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Pediatric Gastroenterology</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassie Timm</last_name>
      <phone>303-790-1515</phone>
      <email>ctimm.rmpgi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Theodore Stathos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Foundation</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecile Guttermuth</last_name>
      <phone>860-585-3838</phone>
      <email>cgutterm@bristolhospital.org</email>
    </contact>
    <investigator>
      <last_name>Salam Zakko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut GI, PC - Research Division</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Tedesco</last_name>
      <phone>(860) 409-4567 xEXT108</phone>
      <email>rtedesco@connecticutgi.org</email>
    </contact>
    <investigator>
      <last_name>David Chaletsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Central Georgia, LLC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Shadwick</last_name>
      <phone>478-464-2600</phone>
      <phone_ext>115</phone_ext>
      <email>kshadwick@gaocg.com</email>
    </contact>
    <investigator>
      <last_name>Shahriar Sedghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology of Southern Indiana</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Walker</last_name>
      <phone>812-206-1702</phone>
      <email>dwalker@aquiant.com</email>
    </contact>
    <investigator>
      <last_name>Steven Harrell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethan Hoover</last_name>
      <phone>319-384-9756</phone>
      <email>ethan-hoover@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Yehudith Assouline-Dayan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinical Research Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Hirst</last_name>
      <phone>785-368-0482</phone>
      <email>hhirst@stormontvail.org</email>
    </contact>
    <investigator>
      <last_name>Curtis Baum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Alexander</last_name>
      <phone>225-231-8783</phone>
      <email>danaa@dhcla.com</email>
    </contact>
    <investigator>
      <last_name>Satyaprasad Alapati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Gastrointestinal Research Group LLP</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Raiser-Vignola</last_name>
      <phone>516-482-5976</phone>
      <email>christineraiser@ligiresearch.com</email>
    </contact>
    <investigator>
      <last_name>MIchael Goldstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Bracken</last_name>
      <phone>919-843-7684</phone>
      <email>catherine_bracken@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Dellon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Schreiner</last_name>
      <phone>980-999-2055</phone>
      <email>rschreiner@crcharlotte.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Johnston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Friedenberg</last_name>
      <email>kafried@roadrunner.com</email>
    </contact>
    <investigator>
      <last_name>Keith Friedenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Endoscopy and Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Normie Stewart-Brown</last_name>
      <phone>713-932-6446</phone>
      <email>n.stewartbrown@workmail.com</email>
    </contact>
    <investigator>
      <last_name>Vikram Jayanty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nephi Georgi</last_name>
      <phone>801-409-2040</phone>
      <email>nephi@advresearch.org</email>
    </contact>
    <investigator>
      <last_name>John Lowe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

